» Articles » PMID: 26416229

The Challenges of Introducing Routine G6PD Testing into Radical Cure: a Workshop Report

Abstract

The only currently available drug that effectively removes malaria hypnozoites from the human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side effects in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. Recently a number of qualitative and a quantitative rapid diagnostic test (RDT) format have been developed that provide an alternative to the current standard G6PD activity assays. The WHO has recently recommended routine testing of G6PD status prior to primaquine radical cure whenever possible. A workshop was held in the Philippines in early 2015 to discuss key challenges and knowledge gaps that hinder the introduction of routine G6PD testing. Two point-of-care (PoC) test formats for the measurement of G6PD activity are currently available: qualitative tests comparable to malaria RDT as well as biosensors that provide a quantitative reading. Qualitative G6PD PoC tests provide a binomial test result, are easy to use and some products are comparable in price to the widely used fluorescent spot test. Qualitative test results can accurately classify hemizygous males, heterozygous females, but may misclassify females with intermediate G6PD activity. Biosensors provide a more complex quantitative readout and are better suited to identify heterozygous females. While associated with higher costs per sample tested biosensors have the potential for broader use in other scenarios where knowledge of G6PD activity is relevant as well. The introduction of routine G6PD testing is associated with additional costs on top of routine treatment that will vary by setting and will need to be assessed prior to test introduction. Reliable G6PD PoC tests have the potential to play an essential role in future malaria elimination programmes, however require an improved understanding on how to best integrate routine G6PD testing into different health settings.

Citing Articles

Optimizing test and treat options for vivax malaria: An options assessment toolkit (OAT) for Asia Pacific national malaria control programs.

Acharya S, Shrestha M, Duc Thang N, Wini L, Habib M, Neukom J PLOS Glob Public Health. 2024; 4(5):e0002970.

PMID: 38776349 PMC: 11111040. DOI: 10.1371/journal.pgph.0002970.


Field evaluation of a novel semi-quantitative point-of-care diagnostic for G6PD deficiency in Indonesia.

Sadhewa A, Panggalo L, Nanine I, Price R, Thriemer K, Satyagraha A PLoS One. 2024; 19(4):e0301506.

PMID: 38687748 PMC: 11060553. DOI: 10.1371/journal.pone.0301506.


Population screening for glucose-6-phosphate dehydrogenase deficiency using quantitative point-of-care tests: a systematic review.

Zailani M, Raja Sabudin R, Ithnin A, Alauddin H, Sulaiman S, Ismail E Front Genet. 2023; 14:1098828.

PMID: 37388931 PMC: 10301741. DOI: 10.3389/fgene.2023.1098828.


The Influence of Cytochrome P450 Polymorphisms on Pharmacokinetic Profiles and Treatment Outcomes Among Malaria Patients in Sub-Saharan Africa: A Systematic Review.

J Marwa K, Kapesa A, Kamugisha E, Swedberg G Pharmgenomics Pers Med. 2023; 16:449-461.

PMID: 37223718 PMC: 10202199. DOI: 10.2147/PGPM.S379945.


Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test among a population at risk of malaria in Myanmar.

Aung T, Suansomjit C, Tun Z, Hlaing T, Kaewkungwal J, Cui L Malar J. 2023; 22(1):143.

PMID: 37127600 PMC: 10150473. DOI: 10.1186/s12936-023-04559-6.


References
1.
Ainoon O, Alawiyah A, Yu Y, Cheong S, Hamidah N, Boo N . Semiquantitative screening test for G6PD deficiency detects severe deficiency but misses a substantial proportion of partially-deficient females. Southeast Asian J Trop Med Public Health. 2003; 34(2):405-14. View

2.
Carlton J, Sina B, Adams J . Why is Plasmodium vivax a neglected tropical disease?. PLoS Negl Trop Dis. 2011; 5(6):e1160. PMC: 3125139. DOI: 10.1371/journal.pntd.0001160. View

3.
Price R, Tjitra E, Guerra C, Yeung S, White N, Anstey N . Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2008; 77(6 Suppl):79-87. PMC: 2653940. View

4.
Brewer G, Powell R, SWANSON S, ALVING A . HEMOLYTIC EFFECT OF PRIMAQUINE. XVII. HEXOKINASE ACTIVITY OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE-DEFICIENT AND NORMAL ERYTHROCYTES. J Lab Clin Med. 1964; 64:601-12. View

5.
Mason P, Bautista J, Gilsanz F . G6PD deficiency: the genotype-phenotype association. Blood Rev. 2007; 21(5):267-83. DOI: 10.1016/j.blre.2007.05.002. View